抗凝治疗6周对比3个月对21岁以下诱发性静脉血栓栓塞患者复发及出血事件的影响:Kids-DOTT随机临床试验
该随机临床试验纳入417例21岁以下急性诱发性静脉血栓栓塞患者,比较抗凝6周(207例)与3个月(210例)的疗效与安全性。符合方案人群297例中,1年症状性复发性静脉血栓栓塞累积发生率6周组0.66%对3个月组0.70%,临床相关出血事件发生率0.65%对0.70%,基于绝对风险差异非劣效性成立。
要点
- 21岁以下诱发性静脉血栓栓塞患者中,抗凝6周对比3个月达到非劣效性标准。
- 1年复发性静脉血栓栓塞累积发生率6周组0.66%对3个月组0.70%。
- 1年临床相关出血事件发生率6周组0.65%对3个月组0.70%。
核心结论
- 在21岁以下诱发性静脉血栓栓塞患者中,抗凝治疗6周对比3个月基于复发性静脉血栓栓塞风险与出血风险之间的权衡达到了非劣效性标准。
研究设计与样本
- 随机临床试验,2008至2021年在5个国家42个中心纳入417例21岁以下急性诱发性静脉血栓栓塞患者。
- 主要排除标准为严重抗凝因子缺乏或既往静脉血栓栓塞。
- 无持续性抗磷脂抗体且诊断后6周复查影像显示血栓已溶解或未完全闭塞的患者进入随机分组。
- 主要终点最终访视于2021年1月完成。
- 干预为抗凝总疗程6周(n=207)对比3个月(n=210)。
主要发现
- 1年症状性复发性静脉血栓栓塞累积发生率:6周抗凝组0.66%(95%CI,0%-1.95%),3个月抗凝组0.70%(95%CI,0%-2.07%)。
- 1年临床相关出血事件发生率:6周抗凝组0.65%(95%CI,0%-1.91%),3个月抗凝组0.70%(95%CI,0%-2.06%)。
- 不良事件发生率:6周抗凝组26%,3个月抗凝组32%。
- 最常见不良事件为发热:6周抗凝组1.9%,3个月抗凝组3.4%。
关键数值与推荐
- 主要疗效与安全性终点为1年内经中心裁定的症状性复发性静脉血栓栓塞和临床相关出血事件,评估对治疗分组设盲。
- 主要分析为符合方案人群的非劣效性分析。
- 非劣效性界值采用双变量权衡,包括症状性复发性静脉血栓栓塞绝对增加0%与临床相关出血事件绝对风险降低4%(双变量非劣效性界值曲线上3个点中的1个)。
- 基于组间复发性静脉血栓栓塞和临床相关出血事件的绝对风险差异,非劣效性成立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. OBJECTIVE: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a conventional 3-month therapy duration in patients younger than 21 years of age. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial involving 417 patients younger than 21 years of age with acute, provoked venous thromboembolism enrolled at 42 centers in 5 countries from 2008-2021. The main exclusions were severe anticoagulant deficiencies or prior venous thromboembolism. Patients without persistent antiphospholipid antibodies and whose thrombi were resolved or not completely occlusive upon repeat imaging at 6 weeks after diagnosis underwent randomization. The final visit for the primary end points occurred in January 2021. INTERVENTIONS: Total duration for anticoagulant therapy of 6 weeks (n = 207) vs 3 months (n = 210) for provoked venous thromboembolism. MAIN OUTCOMES AND MEASURES: The primary efficacy and safety end points were centrally adjudicated symptomatic recurrent venous thromboembolism and clinically relevant bleeding events within 1 year blinded to treatment group. The primary analysis was noninferiority in the per-protocol population. The noninferiority boundary incorporated a bivariate trade-off that included an absolute increase of 0% in symptomatic recurrent venous thromboembolism with an absolute risk reduction of 4% in clinically relevant bleeding events (1 of 3 points on the bivariate noninferiority boundary curve). RESULTS: Among 417 randomized patients, 297 (median age, 8.3 [range, 0.04-20.9] years; 49% female) met criteria for the primary per-protocol population analysis. The Kaplan-Meier estimate for the 1-year cumulative incidence of the primary efficacy outcome was 0.66% (95% CI, 0%-1.95%) in the 6-week anticoagulant therapy group and 0.70% (95% CI, 0%-2.07%) in the 3-month anticoagulant therapy group, and for the primary safety outcome, the incidence was 0.65% (95% CI, 0%-1.91%) and 0.70% (95% CI, 0%-2.06%). Based on absolute risk differences in recurrent venous thromboembolism and clinically relevant bleeding events between groups, noninferiority was demonstrated. Adverse events occurred in 26% of patients in the 6-week anticoagulant therapy group and in 32% of patients in the 3-month anticoagulant therapy group; the most common adverse event was fever (1.9% and 3.4%, respectively). CONCLUSIONS AND RELEVANCE: Among patients younger than 21 years of age with provoked venous thromboembolism, anticoagulant therapy for 6 weeks compared with 3 months met noninferiority criteria based on the trade-off between recurrent venous thromboembolism risk and bleeding risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00687882.
引用
- Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial. JAMA. 2022. PMID: 35015038. doi:10.1001/jama.2021.23182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。